These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36384809)

  • 1. Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.
    Dammer EB; Ping L; Duong DM; Modeste ES; Seyfried NT; Lah JJ; Levey AI; Johnson ECB
    Alzheimers Res Ther; 2022 Nov; 14(1):174. PubMed ID: 36384809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
    Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
    Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.
    Modeste ES; Ping L; Watson CM; Duong DM; Dammer EB; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2023 Jul; 18(1):48. PubMed ID: 37468915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic analysis of Alzheimer's disease cerebrospinal fluid reveals alterations associated with
    Dammer EB; Shantaraman A; Ping L; Duong DM; Gerasimov ES; Ravindran SP; Gudmundsdottir V; Frick EA; Gomez GT; Walker KA; Emilsson V; Jennings LL; Gudnason V; Western D; Cruchaga C; Lah JJ; Wingo TS; Wingo AP; Seyfried NT; Levey AI; Johnson ECB
    Sci Transl Med; 2024 Jun; 16(753):eadn3504. PubMed ID: 38924431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-enriched plasma proteome is significantly altered in Alzheimer's disease.
    Guo Q; Ping L; Dammer EB; Duong DM; Yin L; Xu K; Shantaraman A; Fox EJ; Golde TE; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2024 Oct; 19(1):67. PubMed ID: 39380021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic Network Analysis of Alzheimer's Disease Cerebrospinal Fluid Reveals Alterations Associated with
    Dammer EB; Shantaraman A; Ping L; Duong DM; Gerasimov ES; Ravindran SP; Gudmundsdottir V; Frick EA; Gomez GT; Walker KA; Emilsson V; Jennings LL; Gudnason V; Western D; Cruchaga C; Lah JJ; Wingo TS; Wingo AP; Seyfried NT; Levey AI; Johnson ECB
    medRxiv; 2023 Oct; ():. PubMed ID: 37961720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid.
    Wojtas AM; Dammer EB; Guo Q; Ping L; Shantaraman A; Duong DM; Yin L; Fox EJ; Seifar F; Lee EB; Johnson ECB; Lah JJ; Levey AI; Levites Y; Rangaraju S; Golde TE; Seyfried NT
    Alzheimers Dement; 2024 Jun; 20(6):4043-4065. PubMed ID: 38713744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology.
    Westwood S; Liu B; Baird AL; Anand S; Nevado-Holgado AJ; Newby D; Pikkarainen M; Hallikainen M; Kuusisto J; Streffer JR; Novak G; Blennow K; Andreasson U; Zetterberg H; Smith U; Laakso M; Soininen H; Lovestone S
    Alzheimers Res Ther; 2017 Apr; 9(1):31. PubMed ID: 28441961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review.
    Wesenhagen KEJ; Teunissen CE; Visser PJ; Tijms BM
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):86-98. PubMed ID: 31694431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update.
    Portelius E; Brinkmalm G; Pannee J; Zetterberg H; Blennow K; Dahlén R; Brinkmalm A; Gobom J
    Expert Rev Proteomics; 2017 Nov; 14(11):1007-1020. PubMed ID: 28942688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-enriched plasma proteome is significantly altered in Alzheimer's Disease.
    Guo Q; Ping L; Dammer EB; Yin L; Xu K; Shantaraman A; Fox EJ; Golde TE; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Res Sq; 2024 Feb; ():. PubMed ID: 38464223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.
    Korecka M; Shaw LM
    J Neurochem; 2021 Oct; 159(2):211-233. PubMed ID: 34244999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
    Lizama BN; Williams C; North HA; Pandey K; Duong D; Di Caro V; Mecca AP; Blennow K; Zetterberg H; Levey AI; Grundman M; van Dyck CH; Caggiano AO; Seyfried NT; Hamby ME
    Alzheimers Dement; 2024 Oct; 20(10):6860-6880. PubMed ID: 39166791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.
    Wisch JK; Butt OH; Gordon BA; Schindler SE; Fagan AM; Henson RL; Yang C; Boerwinkle AH; Benzinger TLS; Holtzman DM; Morris JC; Cruchaga C; Ances BM
    Brain; 2023 Jul; 146(7):2944-2956. PubMed ID: 36542469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum.
    Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D
    Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease.
    Lizama BN; North HA; Pandey K; Williams C; Duong D; Cho E; Di Caro V; Ping L; Blennow K; Zetterberg H; Lah J; Levey AI; Grundman M; Caggiano AO; Seyfried NT; Hamby ME
    Neurobiol Dis; 2024 Sep; 199():106575. PubMed ID: 38914170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic Changes in the Human Cerebrovasculature in Alzheimer's Disease and Related Tauopathies Linked to Peripheral Biomarkers in Plasma and Cerebrospinal Fluid.
    Wojtas AM; Dammer EB; Guo Q; Ping L; Shantaraman A; Duong DM; Yin L; Fox EJ; Seifar F; Lee EB; Johnson ECB; Lah JJ; Levey AI; Levites Y; Rangaraju S; Golde TE; Seyfried NT
    medRxiv; 2024 Jan; ():. PubMed ID: 38260316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform.
    Agnello L; Giglio RV; Del Ben F; Piccoli T; Colletti T; Scazzone C; Lo Sasso B; Ciaccio AM; Gambino CM; Salemi G; Ciaccio M
    Sci Rep; 2024 Jul; 14(1):16084. PubMed ID: 38992063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.